Sharda Cropchem Ltd (SHARDACROP)

Chemicals · Agro Chemicals · NSE · Updated 1 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹766.8 ↓ 19.25% (1Y)

🎯 Key Takeaways

  • Sharda Cropchem Ltd is transitioning from a mature agrochemical player into a growth-oriented global specialty chemical exporter, with a strategic shift toward higher-margin non-agrochemical segments and geographic diversification. Despite a 19% YoY decline in 1-year return, recent quarterly performance shows resilient top-line growth and margin expansion, supported by strong regional demand in Europe, NAFTA, and LATAM.
  • Revenue declined 48% QoQ to ₹1,074 in Q1FY27.
  • ⚠️ FX volatility remains a key headwind, as management explicitly cites currency fluctuations impacting profitability despite strong regional growth.
Market Cap
₹6,918
P/E Ratio
11.1
P/B Ratio
2.21
ROE
20.0%
ROCE
25.8%
Debt/Equity
0.00
Div Yield
1.96%
Promoter
74.8%

📖 The Story

Sharda Cropchem Ltd is transitioning from a mature agrochemical player into a growth-oriented global specialty chemical exporter, with a strategic shift toward higher-margin non-agrochemical segments and geographic diversification. Despite a 19% YoY decline in 1-year return, recent quarterly performance shows resilient top-line growth and margin expansion, supported by strong regional demand in Europe, NAFTA, and LATAM. The company maintains a debt-free balance sheet and robust cash reserves, enabling continued investment in registrations and operational efficiency without leverage.

📰 What's Happening

In Q1 FY27, Sharda Cropchem delivered 9% YoY revenue growth to ₹1,074 crores, driven by 15% growth in non-agrochemicals and 16% growth in herbicides, alongside 25% EBITDA growth to ₹178 crores. Management reaffirmed FY27 revenue growth guidance of 10%-15% and projected EBITDA margins of 18%-20%, citing sustained regional volume growth in Europe, NAFTA, and LATAM despite FX volatility and weather-related uncertainties. The company also approved its unaudited financial results and limited review report from B S R & Co. LLP during its July 29 board meeting, confirming transparency in disclosures.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue9291,2892,0651,074
Operating Profit5715840086
OPM %6.1%12.2%19.4%8.0%
Net Profit7414531988
EPS₹8.24₹16.09₹35.32₹9.76

The company's financial trajectory shows a clear inflection point: while PAT declined 38% YoY in Q1 FY27 to ₹88 crores due to lower forex gains, this was not operational weakness — revenue grew 9% YoY, EBITDA rose 25%, and gross margin expanded 120 bps to 36.7%. The sequential decline in revenue and margins from ₹2,065 crores in Q4 FY26 to ₹1,074 crores in Q1 FY27 appears to be a one-time consolidation phase following prior highs, not a structural downturn. Management attributes the current growth trajectory to regional expansion and asset-light model investments, with EBITDA margin improving 220 bps to 16.6% and gross margin up 13% YoY.

🔮 Management Outlook & What's Next

Management has reaffirmed FY27 revenue growth guidance of 10%-15% and projected EBITDA margins of 18%-20%, explicitly linking them to sustained regional volume growth in Europe, NAFTA, and LATAM. In the Q1 FY27 earnings call, management highlighted continued investment in registrations and operational efficiency to support long-term growth, while maintaining financial discipline. No new strategic initiatives were announced beyond geographic expansion and segment diversification, but the reaffirmation of guidance signals confidence in the current trajectory despite macro headwinds.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital90909090
Reserves2,2042,4102,5853,046
Borrowings12840
Total Liabilities3,8324,7254,9035,780
Fixed Assets141061,236
Investments336294555361
Total Assets3,8324,7254,9035,780

The balance sheet reflects a strong capital allocation strategy centered on deleveraging and capital efficiency. Borrowings remain at ₹0 crores across all periods, with total assets growing from ₹4,725 crores in Mar 2025 to ₹5,780 crores in Mar 2026, driven by equity and reserve growth. Equity increased to ₹90 crores with reserves rising from ₹2,410 to ₹3,046 crores, indicating retained earnings are being reinvested rather than distributed. With ₹767 crores in cash reserves as of Q1 FY27, the company is well-positioned to fund global expansion and R&D without external financing, supporting its asset-light model and long-term growth ambitions.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2026
Operating+656
Investing-513
Financing-118
Net Cash Flow+88

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters74.8%74.8%74.8%74.8%
FII5.3%4.2%4.6%3.1%
DII9.3%9.9%9.7%9.2%
Public8.0%8.3%8.0%9.8%
# Shareholders67,29065,56761,15563,572

Institutional investor activity shows a clear trend of accumulation: FII holdings rose from 3.11% in Q1 FY27 to 4.6% in Q4 FY26 and peaked at 5.26% in Q2 FY26, while DII increased from 9.26% to 9.95% over the same period, suggesting growing confidence among foreign and domestic institutional investors. Promoter holding remains stable at 74.82% across all quarters, with no signs of dilution or selling. The rising shareholder base — now at 63,572 investors — reflects increasing market participation and potential liquidity improvement, supporting long-term valuation depth.

⚖️ Peer Comparison — Agro Chemicals

Company MCap (₹ Cr) P/E ROCE ROE D/E
UPL 47,485 23.3 11.4% 6.7% 0.64
PIIND 36,382 31.2 13.3% 10.4% 0.02
SUMICHEM 25,753 44.4 23.1% 17.1% 0.00
BAYERCROP 17,844 369.7 3.3% 1.2% 0.00
SHARDACROP 6,918 11.1 25.8% 20.0% 0.00
DHANUKA 4,360 14.9 27.5% 21.2% 0.03
RALLIS 4,041 24.6 12.9% 9.7% 0.03
NACLIND 3,988 340.5 6.0% 1.8% 0.44
BHAGCHEM 3,683 134.0 6.1% 3.9% 0.33
GSPCROP 2,976 26.0 22.5% 21.9% 0.66

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. FX volatility remains a key headwind, as management explicitly cites currency fluctuations impacting profitability despite strong regional growth. 2. PAT decline of 38% YoY, while driven by forex gains rather than operations, could weigh on investor sentiment if not properly contextualized. 3. Revenue concentration in Europe — down 11% YoY in Q1 FY27 — poses geographic risk, even as NAFTA and LATAM growth offsets it. 4. High promoter ownership (74.82%) may limit float liquidity, potentially increasing volatility during market corrections.

📋 Recent Filings

🧠 Analyst's Read

Sharda Cropchem is executing a disciplined global expansion strategy with improving margins and a strong balance sheet, but near-term PAT volatility from FX movements and regional revenue shifts requires careful monitoring. The company’s ability to sustain 10%-15% revenue growth and expand EBITDA margins to 18%-20% in FY27 will be the critical inflection point for investor confidence.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SHARDACROP files new disclosures

Track SHARDACROP filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHARDACROP — Free

Free account · 2 AI queries/day